Switch theme
Sign up to access all valuation multiples
Medeze Group PCL is engaged in the business of providing stem cell storage, analyzing, isolation, cultivation and preservation services for medical use. It is organised into four reportable segments: Stem cell sample collection service segment; White blood cell potential testing service segment; Other services segment and Sales of products segment.
2010
n/a
LTM Revenue $28.3M
LTM EBITDA $13.8M
$150M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medeze Group has a last 12-month revenue (LTM) of $28.3M and a last 12-month EBITDA of $13.8M.
In the most recent fiscal year, Medeze Group achieved revenue of $25.3M and an EBITDA of $12.6M.
Medeze Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medeze Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $28.3M | XXX | $25.3M | XXX | XXX | XXX |
| Gross Profit | $22.2M | XXX | $19.8M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $13.8M | XXX | $12.6M | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | 50% | XXX | XXX | XXX |
| EBIT | $13.0M | XXX | $11.1M | XXX | XXX | XXX |
| EBIT Margin | 46% | XXX | 44% | XXX | XXX | XXX |
| Net Profit | $11.5M | XXX | $10.3M | XXX | XXX | XXX |
| Net Margin | 41% | XXX | 41% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Medeze Group's stock price is THB 7 (or $0).
Medeze Group has current market cap of THB 7.1B (or $216M), and EV of THB 4.9B (or $150M).
See Medeze Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $150M | $216M | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Medeze Group has market cap of $216M and EV of $150M.
Medeze Group's trades at 5.9x EV/Revenue multiple, and 11.9x EV/EBITDA.
Equity research analysts estimate Medeze Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medeze Group has a P/E ratio of 18.8x.
See valuation multiples for Medeze Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $216M | XXX | $216M | XXX | XXX | XXX |
| EV (current) | $150M | XXX | $150M | XXX | XXX | XXX |
| EV/Revenue | 5.3x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.9x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBIT | 11.6x | XXX | 13.5x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.8x | XXX | 21.0x | XXX | XXX | XXX |
| EV/FCF | -6.3x | XXX | 151.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedeze Group's last 12 month revenue growth is 25%
Medeze Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Medeze Group's rule of 40 is 72% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medeze Group's rule of X is 111% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Medeze Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Growth | 38% | XXX | 30% | XXX | XXX | XXX |
| Rule of 40 | 72% | XXX | 75% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 111% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medeze Group acquired XXX companies to date.
Last acquisition by Medeze Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Medeze Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Medeze Group founded? | Medeze Group was founded in 2010. |
| Where is Medeze Group headquartered? | Medeze Group is headquartered in Thailand. |
| Is Medeze Group publicy listed? | Yes, Medeze Group is a public company listed on BKK. |
| What is the stock symbol of Medeze Group? | Medeze Group trades under MEDEZE ticker. |
| When did Medeze Group go public? | Medeze Group went public in 2024. |
| Who are competitors of Medeze Group? | Similar companies to Medeze Group include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Medeze Group? | Medeze Group's current market cap is $216M |
| What is the current revenue of Medeze Group? | Medeze Group's last 12 months revenue is $28.3M. |
| What is the current revenue growth of Medeze Group? | Medeze Group revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Medeze Group? | Current revenue multiple of Medeze Group is 5.3x. |
| Is Medeze Group profitable? | Yes, Medeze Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medeze Group? | Medeze Group's last 12 months EBITDA is $13.8M. |
| What is Medeze Group's EBITDA margin? | Medeze Group's last 12 months EBITDA margin is 49%. |
| What is the current EV/EBITDA multiple of Medeze Group? | Current EBITDA multiple of Medeze Group is 10.9x. |
| What is the current FCF of Medeze Group? | Medeze Group's last 12 months FCF is -$23.7M. |
| What is Medeze Group's FCF margin? | Medeze Group's last 12 months FCF margin is -84%. |
| What is the current EV/FCF multiple of Medeze Group? | Current FCF multiple of Medeze Group is -6.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
